CTOs on the Move

LEXEO Therapeutics

www.lexeotx.com

 
LEXEO Therapeutics is a New York City-based, fully integrated biotechnology company currently headquartered at the Alexandria Center® for Life Science that aims to apply the transformational science of gene therapy to address some of the world’s most devastating genetic and acquired diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.lexeotx.com
  • 430 East 29th Street 14th Floor
    New York, AB USA 10016
  • Phone: 212.547.9879

Executives

Name Title Contact Details

Funding

LEXEO Therapeutics raised $85M on 01/07/2021

Similar Companies

Homology Medicines

Homology is based on groundbreaking science that harnesses the naturally occurring process of homologous recombination. This non-nuclease-based approach offers clear advantages in its precision, efficiency and on-target in vivo editing of genetic mutations. Homology obtained an exclusive worldwide license to this technology platform, which is based on the pioneering research of Saswati Chatterjee, Ph.D., Professor of Virology at the Beckman Research Institute at the City of Hope in California, member of the Recombinant DNA Advisory Committee (RAC) to the Office of the Director, National Institutes of Health (NIH) and former charter member of the Therapeutic Approaches to Genetic Diseases Study Section of the NIH. Dr. Chatterjee and her team led the first adeno-associated virus (AAV) vector-mediated gene transfer studies into human hematopoietic stem cells and subsequently identified and isolated a series of naturally-occurring AAVs from human CD34+ cells.

Ambrx

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx`s protein engineering technology.

Arteriocyte, Inc.

Arteriocyte, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Alfa Wassermann

Alfa Wassermann, Inc. is a West Caldwell, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healthtech Holdings

HealthTech Holdings Inc. is a health information technology holding company that owns Healthcare Management Systems, MEDHOST and Sentry Healthcare Services.